Longevity Acquisition Corporation (LOAC) to Combine with 4D pharma PLC

4dpharma

Longevity Acquisition Corporation (LOAC) to Combine with 4D pharma PLC

Longevity Acquisition Corporation (NASDAQ:LOAC) announced this morning it has signed a definitive merger agreement with 4D pharma PLC (AIM:DDDD) that would list the company in the US. 4D is developing medications that use human gut bacteria to potentially treat a range of diseases including certain types of cancer, neurodegenerative conditions and autoimmune diseases. The deal
Read More
To access this post, you must purchase a Monthly or Yearly SPACInsider Subscription, or log in if you're a member.

Leave a Reply